Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sight Sciences Inc (SGHT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SGHT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.77
1 Year Target Price $3.77
| 2 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.92% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.32M USD | Price to earnings Ratio - | 1Y Target Price 3.77 |
Price to earnings Ratio - | 1Y Target Price 3.77 | ||
Volume (30-day avg) 8 | Beta 2.45 | 52 Weeks Range 2.03 - 8.45 | Updated Date 06/30/2025 |
52 Weeks Range 2.03 - 8.45 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -63.24% | Operating Margin (TTM) -79.16% |
Management Effectiveness
Return on Assets (TTM) -21.77% | Return on Equity (TTM) -52.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 153496957 | Price to Sales(TTM) 2.85 |
Enterprise Value 153496957 | Price to Sales(TTM) 2.85 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA -4.25 | Shares Outstanding 51702100 | Shares Floating 29345071 |
Shares Outstanding 51702100 | Shares Floating 29345071 | ||
Percent Insiders 20.93 | Percent Institutions 50.82 |
Analyst Ratings
Rating 3 | Target Price 3.77 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sight Sciences Inc
Company Overview
History and Background
Sight Sciences, Inc. was founded in 2011. The company is a commercial-stage medical device company focused on developing and commercializing innovative surgical and non-surgical solutions for ophthalmic diseases, with an emphasis on glaucoma and dry eye disease.
Core Business Areas
- Glaucoma: Develops and markets products for glaucoma surgery, focusing on micro-invasive glaucoma surgery (MIGS).
- Dry Eye Disease: Offers products designed to address the underlying causes of dry eye disease through procedures targeting the meibomian glands.
Leadership and Structure
Paul Badawi is the CEO and co-founder. The company has a typical corporate structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Number of Users: Number of users information not publicly and directly accessible
- OMNI Surgical System: A MIGS device used to treat glaucoma by targeting multiple points of resistance in the conventional outflow pathway. Market share is estimated to be in the 25% range within its specific MIGS sub-segment. Competitors include Glaukos (GKOS), Ivantis (acquired by Alcon), and New World Medical.
- Revenue: Revenue is largely dependent on product sales, estimated at 52.7 million 2023
- Number of Users: Number of users information not publicly and directly accessible
- Revenue: Revenue is largely dependent on product sales, estimated at 14.2 million 2023
- TearCare System: A thermal energy system for treating dry eye disease by applying localized heat to the meibomian glands. Market share is smaller than OMNI and is estimated to be in the 5% of thermal based dry-eye treatments. Competitors include Johnson & Johnson Vision, Lumenis, and Allergan (acquired by AbbVie).
Market Dynamics
Industry Overview
The ophthalmic surgical and dry eye markets are growing due to an aging population and increased prevalence of ophthalmic diseases. Innovation is focused on less invasive procedures and more effective treatments.
Positioning
Sight Sciences is positioned as a company offering innovative, minimally invasive solutions for glaucoma and dry eye. Their competitive advantage lies in their technologies and targeted procedures.
Total Addressable Market (TAM)
The TAM for glaucoma and dry eye treatments is estimated to be in the billions of dollars. Sight Sciences is positioned to capture a portion of this market with their product offerings.
Upturn SWOT Analysis
Strengths
- Innovative products
- Minimally invasive solutions
- Growing revenue
- Proprietary technology
Weaknesses
- Smaller market share compared to larger competitors
- Reliance on sales of OMNI and TearCare systems
- Cash Burn
- Dependence on successful market penetration
Opportunities
- Expanding into new geographic markets
- Developing new products
- Acquiring complementary technologies
- Increasing awareness of dry eye treatments
Threats
- Competition from established players
- Pricing pressure
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GKOS
- ALC
- ABBV
Competitive Landscape
Sight Sciences faces competition from larger, more established medical device companies. To compete, Sight Sciences focuses on innovation and developing targeted solutions for specific ophthalmic conditions.
Growth Trajectory and Initiatives
Historical Growth: Sight Sciences has experienced revenue growth in recent years, driven by increased adoption of its products.
Future Projections: Future growth projections are unavailable without specific analysts estimates.
Recent Initiatives: Recent initiatives include expanding sales efforts and developing new clinical data to support product adoption.
Summary
Sight Sciences is a growing medical device company with innovative products in the glaucoma and dry eye markets. The company's strengths include its technology and minimally invasive solutions. It faces challenges from larger competitors and needs to continue driving market adoption of its products and manage its cash burn.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sight Sciences Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2021-07-15 | Co-Founder, President, CEO & Director Mr. Paul Badawi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 216 | Website https://www.sightsciences.com |
Full time employees 216 | Website https://www.sightsciences.com | ||
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.